The Pax4 Knockout INS-1 Cell Line is a CRISPR/Cas9-mediated gene-disrupted cell line derived from the rat insulinoma INS-1 parental line. This product enables targeted loss-of-function studies of the Pax4 transcription factor in a glucose-responsive pancreatic beta cell background. The engineered disruption abolishes functional Pax4 protein expression, providing a physiologically relevant model for investigating beta cell development and dysfunction.
The INS-1 cell line originates from an X-ray-induced rat insulinoma and retains key characteristics of native pancreatic beta cells, including glucose-stimulated insulin secretion (GSIS) and expression of beta cell-specific transcription factors. These cells are widely used as a model system for studying beta cell biology and diabetes due to their robust insulin secretory response and maintained beta cell identity.
Pax4 functions as a master regulator of pancreatic beta cell identity, directly activating insulin (INS) and pro-survival factor Bcl-xL (BCL2L1) transcription. Upstream, NEUROG3, Notch ligands DLL1 and JAG1, and Wnt signals via WNT3A, FZD, and CTNNB1 coordinate its expression. Pax4 collaborates with PDX1 and MAFA to sustain the beta cell program, while interacting with HDACs and TLE corepressors to silence alternative endocrine genes. It also maintains expression of PDX1, MAFA, NKX6-1, and CCND1, linking PI3K-AKT-mediated survival to insulin secretion.
Disruption of Pax4 in INS-1 cells results in diminished expression of beta cell markers, severely impaired glucose-stimulated insulin secretion, and increased apoptotic susceptibility. This knockout phenotype mirrors key features of beta cell failure in diabetes, including reduced insulin output and compromised cell survival. Consequently, this cell line provides a robust platform for studying Pax4-dependent regulatory networks and for evaluating therapeutic interventions aimed at restoring beta cell function.
Typical applications include mechanistic investigations of beta cell dysfunction in type 1 and type 2 diabetes, compound screening for protective agents, and detailed analyses of Pax4 transcriptional targets via ChIP-qPCR. Compatible assays comprise GSIS, insulin ELISA, qRT-PCR for INS and PDX1, Western blot for Bcl-xL, apoptosis detection by Annexin V/propidium iodide flow cytometry, and immunofluorescence for insulin. This knockout model also supports co-culture and differentiation studies. For advanced technical support or custom inquiries, please contact Ascent Research.
